daratumumab,talquetamab,teclistamab,pomalidomide
janssen,genmab
['trimm-2', 'mmsm', 'daratumumab', 'talquetamab']
lower rates of infection with talquetamab-daratumumab combo (than talq-tec) in updated trimm-2 results, but still infections reported in limited detail. 10.8% had opportunistic infections low rates of ivig use. #asco23 #mmsm 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem